Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma

Table 4 Ongoing phase II/III clinical trials involving targeted agents for patients with advanced or metastatic non-small cell lung cancer

Study design	Clinical trial ID	Phase	Status	Key entry criteria
EGFR inhibition
Erlotinib vs docetaxel	NCT00637910	III	Recruiting	WT EGFR, prior platinum chemo, no prior taxanes
Erlotinib vs pazopanib	NCT01027598	II	Active, not recruiting	1 prior chemo
Erlotinib + OSI-906	NCT01221077	II	Recruiting	EGFR mutation (+), chemotherapy-naive
Erlotinib + ARQ197	NCT01377376	III	Recruiting	WT EGFR, prior platinum-based chemo
Erlotinib + ARQ197	NCT01244191	III	Recruiting	2 prior lines of chemo
Erlotinib + PC + Bev	NCT00976677	II	Active, not recruiting	Non-squamous, nonsmokers
Gefitinib (maintenance)	NCT01404260	III	Active, not recruiting	Stable disease after chemo, EGFR unknown, never or light smokers
Gefitinib vs Pem	NCT00891579	II	Recruiting	WT EGFR, prior platinum-based chemo
Afatinib	NCT00525148	II	Active, not recruiting	EGFR mutation (+)
Afatinib	NCT00711594	II	Active, not recruiting	Prior platinum-based chemo, progressed after erlotinib or gefitinib
PF00299804	NCT01000025	III	Recruiting	1 prior chemo
PF00299804 vs erlotinib	NCT01360554	III	Recruiting	1 prior chemo
BRAF inhibition
AZD6244 + erlotinib	NCT01229150	II	Recruiting	KRAS WT or KRAS mutant
Dasatinib	NCT01514864	II	Recruiting	Tumors harboring DDR2 mutation or inactivating B-RAF mutation
AKT inhibition
MK-2206 + erlotinib	NCT01294306	II	Recruiting	Progressed after initial response to erlotinib
MEK inhibition
GSK2118436	NCT01336634	II	Recruiting	BRAF mutation (+)
HDAC inhibitor
Vorinostat + gefitinib	NCT01027676	II/III	Recruiting	prior platinum-based chemo
Vorinostat + bortezomib	NCT00798720	II	Completed recruiting	2 prior chemo
Belinostat + Bev + PC	NCT01090830	II	Recruiting	Chemotherapy-naive
LBH589 + Pem	NCT00907179	II	Recruiting	1 prior chemo
KRAS mutations
AZD6244 + erlotinib	NCT01229150	II	Recruiting	Prior platinum-based chemo
Erlotinib + ARQ197 vs single-agent chemo	NCT01395758	II	Recruiting	KRAS mutation (+)
GSK1120212 vs docetaxel	NCT01362296	II	Recruiting	KRAS mutation (+)

PC: Paclitaxel and carboplatin; Bev: Bevacizumab; Pem: Pemetrexed; NSCLC: Non-small cell lung cancer; chemo: Chemotherapy; WT: Wild-type; EGFR: Epidermal growth factor receptor; HDAC: Histone deacetylase inhibitor.